SOHO 2024 live congress feed

Stay up to date with the latest developments in ALL from the SOHO 2024 Annual Meeting with our live social media coverage.

CONGRESS | #SOHO2024 |
Elias Jabbour, @MDAndersonNews shares data of D-D Mini-HCVD-inotuzumab-blinatumomab for the treatment of R/R ALL; concluding with the feasibility of the combination based on safety and efficacy data. Overall 1-year OS 90% vs 66%.#ALLsm #leusm pic.twitter.com/F93s1biTkK

— ALL Hub (@ALL_Hub_) September 6, 2024

CONGRESS | POSTER | #SOHO2024 |
Ajibade Ashaye presents a comparison of the effects of ponatinib vs imatinib in newly diagnosed Ph+ ALL on patient-reported outcomes from the phase III PhALLCON trial (PRO evaluable population N=238).
Ponatinib was associated with significant and… pic.twitter.com/0Xpz7aFBrf

— ALL Hub (@ALL_Hub_) September 5, 2024

CONGRESS | POSTER | #SOHO2024 |
Elias Jabbour, MD @MDAndersonNews presents an in-depth responder analysis of the phase III PhALLCON trial investigating ponatinib vs imatinib in newly diagnosed Ph+ ALL (N=245).
Pts receiving ponatinib experienced clinically meaningful and… pic.twitter.com/iPiGFN8mF5

— ALL Hub (@ALL_Hub_) September 5, 2024

CONGRESS | POSTER | #SOHO2024 |
Ajibade Ashaye presents an analysis of MRD-negative complete remission as a prognostic indicator of long-term survival outcomes (OS and EFS) in pts with Ph+ ALL from a systemic literature review.
Deeper responses at end of induction/end of… pic.twitter.com/eHfgYdEf1o

— ALL Hub (@ALL_Hub_) September 5, 2024

CONGRESS | #SOHO2024
Rayne Rouce @bcmhouston presents on the evolution of tisagenlecleucel for the treatment of pediatric and young adult R/R B-ALL.
Safety outcomes were favorable and did not change greatly, patients are receiving tisagenleucel earlier in their treatment course,… pic.twitter.com/MM9LzOiZHP

— ALL Hub (@ALL_Hub_) September 4, 2024

CONGRESS | #SOHO2024 |
Josep Maria Ribera @CarrerasIJC debates that Ph + ALL is best treated with chemotherapy and transplant; concluding that in most cases allo-HSCT is important with 1st or 2nd gen TKI and in 3rd gen TKI where there is a lack of CMR or IKZF1+ signature.#ALLsm… pic.twitter.com/kZQMinWIkU

— ALL Hub (@ALL_Hub_) September 4, 2024

CONGRESS | #SOHO2024
Elias Jabbour, @MDAndersonNews debates that Ph + ALL can be treated with chemotherapy free regimens and without transplant. Key points include: omit allo-SCT in certain patients who could be cured without , CAR T could be considered, and new drugs to be… pic.twitter.com/ZEN3v57WhJ

— ALL Hub (@ALL_Hub_) September 4, 2024

CONGRESS | #SOHO2024 |
Partow Kebriaei @MDAndersonNews provides an overview on transplant in #ALL. Key points include: MRD is the leading factor to determine transplant, transplant may be considered in first remission, and transplant consolidation after CAR T may be effective in… pic.twitter.com/i8zxDfiB7q

— ALL Hub (@ALL_Hub_) September 4, 2024

Only 1 day to go! 

The ALL Hub will be covering #SOHO2024.

Sep 4–7 
Houston, US, and online 

We’ll be providing live social media coverage.
Keep an eye on our socials to see the latest updates!

#allsm #leusm @SocietyofHemOnc pic.twitter.com/rnQ22bXnTX

— ALL Hub (@ALL_Hub_) September 3, 2024

CONGRESS | #SOHO2024 @MRLitzow @MayoClinic discusses incorporating immunotherapies, blinatumomab and InO, into upfront #ALL therapy; concluding that both these agents can improve outcomes in MRD- ALL and may be combined with or sequenced with chemotherapy.#ALLsm #leusm pic.twitter.com/7oUO0GLP2t

— ALL Hub (@ALL_Hub_) September 4, 2024